

## IN THE CLAIMS

Please cancel claims 17, 21, 25, 30, and 75-77, without prejudice or disclaimer. Please add following new claims 78-88.

---

78. (New) A method for identifying an antagonist of MCK-10, comprising:

(a) contacting a cell line that expresses either (i) an MCK-10 protein comprising the amino acid sequence of SEQ ID NO. 2, or (ii) a splice variant thereof, with a test compound; and

(b) determining whether said test compound inhibits the binding of a ligand to said MCK-10 protein or splice variant thereof,

wherein a test compound that inhibits binding of a ligand to said MCK-10 protein or splice variant thereof, is an antagonist of MCK-10.

79. (New) The method of claim 78, wherein said cell line is a genetically engineered cell line.

80. (New) The method of claim 78, wherein said cell line endogenously expresses the MCK-10.

81. (New) A method for identifying an antagonist of MCK-10, comprising:

(a) contacting a cell line that expresses either (i) an MCK-10 protein comprising the amino acid sequence of SEQ ID NO. 2, or (ii) a splice variant thereof, with a test compound; and

(b) determining whether said test compound inhibits the binding of a ligand to said MCK-10 protein or splice variant thereof thereby effecting a

cellular change in said cell line, wherein a test compound that effects a cellular change in said cell line is an antagonist of MCK-10.

82. (New) A method for identifying a peptide that binds to MCK-10, comprising:

(a) contacting an MCK-10 protein comprising the amino acid sequence of SEQ ID NO. 2, or a splice variant thereof, with a random peptide library;

(b) isolating a complex comprising an (i) MCK-10 protein, or splice variant thereof, and (ii) a peptide; and

(c) determining the sequence of the peptide of said complex.

83. (New) A method for identifying a compound that affects MCK-10 activity, comprising:

(a) contacting a cell line that expresses either (i) an MCK-10 protein comprising the amino acid sequence of SEQ ID NO. 2, or (ii) a splice variant thereof, with a test compound; and

(b) determining whether said test compound modulates the activity of said MCK-10 protein or splice variant thereof.

84. (New) The method of claim 83, wherein said test compound inhibits the activity of said MCK-10 protein or splice variant thereof.

85. (New) A method for identifying an antagonist of MCK-10, comprising:

(a) contacting an MCK-10 protein comprising the amino acid sequence of SEQ ID NO. 2, or a splice variant thereof, with a test compound; and

(b) determining whether said test compound inhibits the binding of a ligand to said MCK-10 protein or splice variant thereof,

wherein a test compound that inhibits binding of a ligand to said MCK-10 protein or splice variant thereof, is an antagonist of MCK-10.

86. (New) A method for identifying a compound that affects MCK-10 activity, comprising:

(a) contacting an MCK-10 protein comprising the amino acid sequence of SEQ ID NO. 2, or a splice variant thereof, with a test compound; and

(b) determining whether said test compound modulates the activity of said MCK-10 protein or splice variant thereof.

87. (New) The method of claim 86, wherein said test compound inhibits the activity of said MCK-10 protein or splice variant thereof.

---